Compare Amylx Pharmaceuticals Inc (AMLX) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Southwest Airlines Co — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while Southwest Airlines Co trades at $47.88 (market cap $23.67B). The key difference: Southwest Airlines Co is far larger — about 12× Amylx Pharmaceuticals Inc's market cap, and Southwest Airlines Co pays a 1.49% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | LUV | |
|---|---|---|
Market Cap | $1.98B | $23.67B |
Sector | Health | Industrials |
52-Week High | $18.70 | $54.80 |
52-Week Low | $7.64 | $29.06 |
Enterprise Value | $1.70B | $26.74B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Southwest Airlines (LUV) trades at $48.43, down 1.61% today, with a bullish technical signal from moving averages and RSI near oversold levels. The company reported mixed Q1 2026 earnings, missing estimates, but maintains a positive outlook with Q2 2026 EPS expected at $0.52. Recent news highlights sector tailwinds from lower fuel costs and a partnership with AWS to accelerate AI capabilities by 2028.
LUV presents a balanced risk-reward profile with a consensus price target of $52.47, offering ~8% upside. Key opportunities include earnings growth potential and favorable industry dynamics, while risks involve Boeing 737 MAX incidents and volatile fuel prices. Analyst sentiment is mixed, with 42% buy ratings, reflecting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
